Primary Mediastinal Large B-cell Lymphoma

Primary mediastinal B-cell lymphoma (PMBCL) is a relatively rare lymphoma subtype affecting mainly young adults. Its molecular signature and clinical features resemble classical Hodgkin lymphoma. The optimal chemotherapy for this lymphoma subtype has not been established. The addition of rituximab t...

Full description

Saved in:
Bibliographic Details
Published inCurrent hematologic malignancy reports Vol. 9; no. 3; pp. 273 - 283
Main Authors Dabrowska-Iwanicka, Anna, Walewski, Jan A.
Format Journal Article
LanguageEnglish
Published Boston Springer US 01.09.2014
Subjects
Antibodies, Monoclonal, Murine-Derived - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cyclophosphamide - therapeutic use
Doxorubicin - therapeutic use
Geriatrics/Gerontology
Hematology
Humans
Immunotherapy
Lymphoma, B-Cell - diagnosis
Lymphoma, B-Cell - genetics
Lymphoma, B-Cell - pathology
Lymphoma, B-Cell - therapy
Lymphomas (G Nowakowski
Lymphomas (G Nowakowski, Section Editor)
Medicine
Medicine & Public Health
Oncology
Positron-Emission Tomography
Prednisone - therapeutic use
Prognosis
Rituximab
Section Editor
Stem Cell Transplantation
Vincristine - therapeutic use
International prognostic index
Chemotherapy
Immunochemotherapy
Programmed death ligand (PD-L)
PET/CT
Rituximab
Third-generation regimen
Primary mediastinal B-cell lymphoma
Radiotherapy
JAK-STAT pathway
Online AccessGet full text

Cover

Abstract Primary mediastinal B-cell lymphoma (PMBCL) is a relatively rare lymphoma subtype affecting mainly young adults. Its molecular signature and clinical features resemble classical Hodgkin lymphoma. The optimal chemotherapy for this lymphoma subtype has not been established. The addition of rituximab to anthracycline based chemotherapy improved response rates and survival. Many centers use R-CHOP as standard treatment, but the role of the intensified regimens and consolidation radiotherapy has to be clarified. Recent data coming from retrospective analyses and an ongoing prospective study addressing the problem of consolidation radiotherapy will help to better identify risk groups and apply risk-adapted and effective treatment strategies. The latest research has helped to understand molecular mechanisms of PMBCL pathogenesis and indicated targets of directed therapy for the future.
AbstractList Primary mediastinal B-cell lymphoma (PMBCL) is a relatively rare lymphoma subtype affecting mainly young adults. Its molecular signature and clinical features resemble classical Hodgkin lymphoma. The optimal chemotherapy for this lymphoma subtype has not been established. The addition of rituximab to anthracycline based chemotherapy improved response rates and survival. Many centers use R-CHOP as standard treatment, but the role of the intensified regimens and consolidation radiotherapy has to be clarified. Recent data coming from retrospective analyses and an ongoing prospective study addressing the problem of consolidation radiotherapy will help to better identify risk groups and apply risk-adapted and effective treatment strategies. The latest research has helped to understand molecular mechanisms of PMBCL pathogenesis and indicated targets of directed therapy for the future.
Author Walewski, Jan A.
Dabrowska-Iwanicka, Anna
Author_xml – sequence: 1
  givenname: Anna
  surname: Dabrowska-Iwanicka
  fullname: Dabrowska-Iwanicka, Anna
  email: adab@coi.waw.pl
  organization: Department of Lymphoid Malignancies, Maria Sklodowska-Curie Institute and Oncology Centre
– sequence: 2
  givenname: Jan A.
  surname: Walewski
  fullname: Walewski, Jan A.
  organization: Department of Lymphoid Malignancies, Maria Sklodowska-Curie Institute and Oncology Centre
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24952250$$D View this record in MEDLINE/PubMed
BookMark eNp9kEtLAzEQx4NU7EM_gBfp1cPqTLLZ3V4ELb6gogcFb2GSzbZb9lGSttBvb8pq0YuXeTDz_8_wG7Je0zaWsXOEKwRIrz1iNplEgHEEHENxxAYoZRZlnH_2DjVinw29XwLEMYI4YX0eTyTnEgbs8s2VNbnd-MXmJfl12VA1npGb2_FdZGwVml29WrQ1nbLjgipvz77ziH083L9Pn6LZ6-Pz9HYWGYl8HZHkKAiIxzZF0EkqjM4JE6CEG6lFlqIteJLrAkhKYYkbYTLIc61tCKkYsZvOd7XRtc2NbdaOKrXq_lQtlervpCkXat5uVYwZAI-DAXYGxrXeO1sctAhqz0113FTgpvbcFATNxe-jB8UPqLDAuwUfRs3cOrVsNy7A8v-4fgH0bnsZ
CitedBy_id crossref_primary_10_3390_cancers14122912
crossref_primary_10_1016_j_clml_2021_06_012
crossref_primary_10_1186_s12885_019_6303_z
crossref_primary_10_2214_AJR_19_21225
crossref_primary_10_3389_fonc_2021_662211
crossref_primary_10_1016_j_blre_2019_100640
crossref_primary_10_18632_oncotarget_25892
crossref_primary_10_1159_000448159
crossref_primary_10_1016_j_ctrv_2015_04_006
crossref_primary_10_1111_bjh_15051
crossref_primary_10_1016_j_clml_2017_10_007
crossref_primary_10_1002_pbc_31065
crossref_primary_10_1016_j_radcr_2021_01_063
crossref_primary_10_1080_10428194_2017_1375100
crossref_primary_10_18632_oncotarget_12988
crossref_primary_10_3390_cells12010196
crossref_primary_10_1016_j_adro_2022_101090
crossref_primary_10_4103_ccij_ccij_77_19
crossref_primary_10_1177_1040638719875501
crossref_primary_10_1016_j_crwh_2018_e00065
crossref_primary_10_1186_s43055_022_00825_w
crossref_primary_10_7759_cureus_16128
crossref_primary_10_1007_s00280_016_3024_8
crossref_primary_10_2147_JBM_S393180
Cites_doi 10.1007/s00277-008-0625-2
10.1038/sj.bmt.1703401
10.1111/j.1365-2141.2005.05661.x
10.3109/10428194.2011.573032
10.1200/JCO.2006.09.2403
10.1002/gcc.20420
10.1158/1078-0432.CCR-13-3007
10.1111/j.1365-2559.2009.03462.x
10.1182/blood.V116.21.420.420
10.1200/jco.2008.26.15_suppl.19506
10.1056/NEJMoa1214561
10.3109/10428194.2012.746684
10.1182/blood.V98.9.2762
10.1182/blood-2004-09-3701
10.1182/blood-2012-04-422709
10.1182/blood.V87.4.1571.bloodjournal8741571
10.1084/jem.20031074
10.1200/JCO.1993.11.12.2306
10.1007/s11899-011-0090-1
10.1080/10428190802108870
10.1182/blood.V122.21.3046.3046
10.1182/blood-2003-10-3545
10.1182/blood-2004-12-4901
10.3816/CLM.2009.n.074
10.1097/01.MP.0000032534.81894.B3
10.1093/annonc/mdj030
10.1182/blood.V122.21.638.638
10.1182/blood.V94.10.3567.422k06_3567_3575
10.1007/s00277-014-2043-y
10.3109/10428194.2013.810738
10.1182/blood.V122.21.4302.4302
10.1038/modpathol.2012.182
10.1158/1078-0432.CCR-13-0855
10.1182/blood-2003-06-1841
10.1038/sj.bjc.6601460
10.1182/blood.V120.21.303.303
10.1182/blood-2009-03-209759
10.1080/10428190802203788
10.1016/j.critrevonc.2008.07.020
10.1097/00000478-200110000-00008
10.1002/hon.2012
10.1182/blood-2010-05-282780
10.1634/theoncologist.2011-0275
10.1200/JCO.1999.17.8.2479
10.1038/nature09754
10.1056/NEJMoa1200690
10.1084/jem.20090528
10.1093/annonc/mdq418
10.1182/asheducation-2008.1.349
10.1016/S0002-9440(10)63815-1
10.1093/oxfordjournals.annonc.a059016
10.1038/ng.2900
10.1182/blood-2012-06-437210
10.1182/blood-2005-11-4742
10.1182/blood.V114.22.133.133
10.1002/ajh.22165
10.1182/blood-2013-10-535443
10.1016/j.ijrobp.2013.05.053
10.1182/blood-2011-05-326538
ContentType Journal Article
Copyright The Author(s) 2014
Copyright_xml – notice: The Author(s) 2014
DBID C6C
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
5PM
DOI 10.1007/s11899-014-0219-0
DatabaseName SpringerOpen (Open Access)
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
DatabaseTitleList

MEDLINE
Database_xml – sequence: 1
  dbid: C6C
  name: SpringerOpen (Open Access)
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1558-822X
EndPage 283
ExternalDocumentID 10_1007_s11899_014_0219_0
24952250
Genre Journal Article
GroupedDBID ---
-5E
-5G
-BR
-EM
-Y2
-~C
.86
.VR
06C
06D
0R~
0VY
203
29F
29~
2J2
2JN
2JY
2KG
2KM
2LR
2VQ
2~H
30V
4.4
406
408
40E
53G
5GY
5VS
6NX
875
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AAFGU
AAHNG
AAIAL
AAJKR
AANXM
AANZL
AAPBV
AARHV
AARTL
AATNV
AATVU
AAUYE
AAWCG
AAYFA
AAYIU
AAYQN
AAYTO
ABDZT
ABECU
ABFGW
ABFTV
ABHQN
ABJNI
ABJOX
ABKAS
ABKCH
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABSXP
ABTEG
ABTKH
ABTMW
ABWNU
ABXPI
ACBMV
ACBRV
ACBYP
ACGFS
ACHSB
ACHXU
ACIGE
ACIPQ
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACTTH
ACVWB
ACWMK
ADHHG
ADHIR
ADINQ
ADKNI
ADKPE
ADMDM
ADOXG
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEBTG
AEFTE
AEGAL
AEGNC
AEJHL
AEJRE
AENEX
AEOHA
AEPYU
AESKC
AESTI
AETLH
AEVLU
AEVTX
AEXYK
AFLOW
AFNRJ
AFQWF
AFWTZ
AFZKB
AGAYW
AGDGC
AGGBP
AGJBK
AGMZJ
AGQMX
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHSBF
AHYZX
AIAKS
AIIXL
AILAN
AIMYW
AITGF
AJBLW
AJDOV
AJRNO
AJZVZ
AKQUC
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
AXYYD
B-.
BA0
BDATZ
BGNMA
C6C
CAG
COF
CS3
CSCUP
CUW
DDRTE
DNIVK
DPUIP
EBD
EBLON
EBS
EIOEI
EJD
EMOBN
ESBYG
F5P
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
HF~
HG6
HMJXF
HRMNR
HZ~
IJ-
IKXTQ
IWAJR
IXC
IXD
IXE
I~Z
J-C
JBSCW
JZLTJ
KOV
LLZTM
M4Y
MA-
NPVJJ
NQJWS
NU0
O9-
O9J
P9S
PF0
PT4
QOR
QOS
R89
R9I
ROL
RPX
RSV
S16
S1Z
S27
S37
S3B
SAP
SDH
SHX
SISQX
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
TSG
TSK
TSV
TUC
U2A
U9L
UG4
UNUBA
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W48
WK8
YLTOR
Z7U
Z82
Z83
Z87
ZMTXR
ZOVNA
~A9
AACDK
AAJBT
AASML
ABAKF
ACAOD
ACDTI
ACZOJ
AEFQL
AEMSY
AFBBN
AGQEE
AGRTI
AIGIU
CGR
CUY
CVF
ECM
EIF
H13
NPM
SJYHP
AAYXX
CITATION
5PM
ID FETCH-LOGICAL-c512t-a5213a0a24e710b673cbda160a62c5b3871ef26dbf0a553ea2c3c80ddbbeddb73
IEDL.DBID AGYKE
ISSN 1558-8211
IngestDate Tue Sep 17 21:10:38 EDT 2024
Thu Sep 12 18:54:19 EDT 2024
Sat Sep 28 08:28:31 EDT 2024
Sat Dec 16 11:59:38 EST 2023
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords International prognostic index
Chemotherapy
Immunochemotherapy
Programmed death ligand (PD-L)
PET/CT
Rituximab
Third-generation regimen
Primary mediastinal B-cell lymphoma
Radiotherapy
JAK-STAT pathway
Language English
License Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c512t-a5213a0a24e710b673cbda160a62c5b3871ef26dbf0a553ea2c3c80ddbbeddb73
OpenAccessLink https://proxy.k.utb.cz/login?url=http://link.springer.com/10.1007/s11899-014-0219-0
PMID 24952250
PageCount 11
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_4180024
crossref_primary_10_1007_s11899_014_0219_0
pubmed_primary_24952250
springer_journals_10_1007_s11899_014_0219_0
PublicationCentury 2000
PublicationDate 2014-09-01
PublicationDateYYYYMMDD 2014-09-01
PublicationDate_xml – month: 09
  year: 2014
  text: 2014-09-01
  day: 01
PublicationDecade 2010
PublicationPlace Boston
PublicationPlace_xml – name: Boston
– name: United States
PublicationTitle Current hematologic malignancy reports
PublicationTitleAbbrev Curr Hematol Malig Rep
PublicationTitleAlternate Curr Hematol Malig Rep
PublicationYear 2014
Publisher Springer US
Publisher_xml – name: Springer US
References Pileri S, Gaidano G, Zinzani P, et al. Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins. Am J Pathol. 2003;162(1):243–53.
Papageorgiou SG, Diamantopoulos P, Levidou G, et al. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without rituximab. Hematol Oncol. 2013;31(1):10–7.
Soumerai JD, Hellmann MD, Feng Y, et al. Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease. Leuk Lymphoma. 2014;55(3):538–43. This paper describes the presence of a high rate of primary refractory disease especially in poor-risk patients and indicates need for intensification/novel therapies in this patient population.
Rodriguez J, Conde E, Gutiérrez A, et al. Primary mediastinal large cell lymphoma (PMBCL): frontline treatment with autologous stem cell transplantation (ASCT). The GEL-TAMO experience. Hematol Oncol. 2008;26(3):171–8.
Lazzarino M, Orlandi E, Paulli M, et al. Primary mediastinal B-cell lymphoma with sclerosis: an aggressive tumor with distinctive clinical and pathological features. J Clin Oncol. 1993;11(12):2306–13.
Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;368(15):1408–16. This important study confirms the high activity of intensified immunochemotherapy regimen inducing long remissions. Notably, very good survival rates were achieved without consolidation radiotherapy.
Vassilakopoulos TP, Pangalis G, Katsigiannis A, et al. Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care. Oncologist. 2012;17(2):239–49. One of the larger retrospective studies showing superiority of R-CHOP over CHOP regimen.
Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116(17):3268–77. This research paper reveals an important correlation between genetic alterations – 9p24.1 amplification and PD-1 ligand expression, being potential therapeutic targets.
Harris NL. Shades of grey between large B-cell lymphomas and Hodgkin lymphomas: differential diagnosis and biological implications. Mod Pathol. 2013;26:S57–70.
TopalianFSHodiFSBrahmerJRSafety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med2012366262443542265812710.1056/NEJMoa12006901:CAS:528:DC%2BC38XhtV2rs7fN3544539
Zinzani PL, Martelli M, Bertini M, et al. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica. 2002;87(12):1258–64.
Twa DD, Chan FC, Ben-Neriah S, et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood. 2014;123(13):2062–5.
SteidlCGascoyneRThe molecular pathogenesis of primary mediastinal large B-cell lymphomaBlood2011118102659692170077010.1182/blood-2011-05-3265381:CAS:528:DC%2BC3MXht1ans7nOThis extensive review explains all important molecular and immunological pathological mechanisms leading to the malignant phenotype of PMBCL
Weniger MA, Gesk S, Ehrlich S, et al. Gains of REL in primary mediastinal B-cell lymphoma coincide with nuclear accumulation of REL protein. Genes Chromosome Cancer. 2007;46(4):406–15.
Martelli M, Ferreri AJ, Johnson P. Primary mediastinal large B-cell lymphoma. Crit Rev Oncol Hematol. 2008;68(3):256–63.
Fietz T, Knauf WU, Haenel M, et al. Treatment of primary mediastinal large B cell lymphoma with an alternating chemotherapy regimen based on high dose methotrexate. Ann Hematol. 2009;88(5):433–9.
SchmitzRHansmannMLBohleVTNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B-cell lymphomaJ Exp Med2009206598191938063910.1084/jem.200905281:CAS:528:DC%2BD1MXlvVGmtbg%3D2715030
Moskowitz C, Hamlin PA, Maragulia J, et al. Sequential Dose-Dense RCHOP Followed by ICE Consolidation (MSKCC protocol 01–142) without Radiotherapy for Patients with Primary Mediastinal Large B Cell Lymphoma. ASH Annual Meet Abstr. 2010;116(21):420.
Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–86.
Kuruvilla J, Pintilie M, Tsang R, et al. Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma. Leuk Lymphoma. 2008;49(7):1329–36.
De Leval L, Ferry JA, Falini B, et al. Expression of bcl-6 and CD10 in primary mediastinal large B-cell lymphoma. Evidence for derivation from germinal center B cells? Am J Surg Pathol. 2001;25(10):1277–82.
Melzner I, Bucur AJ, Bruderlein S, et al. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood. 2005;105(6):2535–42.
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri S, Stein H, Thiele J, Vardiman J (eds). WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. 4th edn. Lyon: IARC; 2008; pp250-251
XuLMFangHWangWHPrognostic significance of rituximab and radiotherapy for patients with primary mediastinal large B-cell lymphoma receiving doxorubicin-containing chemotherapyLeuk Lymphoma20135481684902313707010.3109/10428194.2012.7466841:CAS:528:DC%2BC3sXhtFWlu77E
Nagle SJ, Cong EA, Chekoi S, et al. The role of PET imaging for predicting treatment failure in primary mediastinal B-cell lymphoma. ASH Annual Meet Abstr. 2013;122(21):4302.
Avigdor A, Sirotkin T, Kedmi M et al. The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma. Ann Hematol 2014, published online March 5th.
Savage KJ, Al-Rajhi N, Voss N, et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol. 2006;17(1):122–30.
De MelloCDe AndradeVDe LimaVPrognostic impact of MUM1 expression by immunohistochemistry on primary mediastinal large B-cell lymphomaLeuk Lymphoma201152814955032162369210.3109/10428194.2011.573032
Hoeller S, Zihler D. Zlobec I. BOB.1, CD79a and cyclin E are the most appropriate markers to discriminate classical Hodgkin’s lymphoma from primary mediastinal large B-cell lymphoma. Histopathology. 2010(2);56:217–28.
RitzOGuiterCCastellanoFRecurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphomaBlood200911461236421942372610.1182/blood-2009-03-2097591:CAS:528:DC%2BD1MXhtVSgsbfE2824656
LeithauserFBauerleMHuynhMQMollerPIsotype-switched immunoglobulin genes with a high load of somatic hypermutation and lack of ongoing mutational activity are prevalent in mediastinal B-cell lymphomaBlood20019892762701167534910.1182/blood.V98.9.27621:CAS:528:DC%2BD3MXotVegsbs%3D
SteidlCShahSPWoolcockBWMHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancersNature20114717338377812136875810.1038/nature097541:CAS:528:DC%2BC3MXis1Ckur0%3D3902849
Copie-Bergman C, Plonquet A, Alonso MA, et al. MAL expression in lymphoid cells: further evidence for MAL as a distinct molecular marker of primary mediastinal large B-cell lymphomas. Mod Pathol. 2002;15(11):1172–80.
Roberts RA, Wright G, Rosenwald A, et al. Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival. Blood. 2006;108(1):311–8.
RodriguezJPughWCRomagueraJEPrimary mediastinal large cell lymphoma is characterized by an inverted pattern of large tumoral mass and low beta 2 microglobulin levels in serum and frequently elevated levels of serum lactate dehydrogenaseAnn Oncol199459847978488871:STN:280:DyaK2M7ltFKjtg%3D%3D
Hao Y, Chapuy B, Monti S et al. Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma in vitro and in vivo. Clin Cancer Res. 2014;20(10):2674–83. This recent paper confirms antitumor activity of the JAK2 inhibitor in a pre-clinical setting, showing the way for development of new therapeutic agents.
Savage KJ, Yenson PR, Shenkier T, et al. The outcome of primary mediastinal large B cell lymphoma (PMBCL) in the R-CHOP treatment era. ASH Annual Meet Abstr. 2012;120(21):303. The retrospective study including 176 patients confirms good outcome of R-CHOP-treated patients and is a good example of encouraging results of a PET-guided approach to radiotherapy, omitting IFRTH in PET-negative patients.
Farinha P, Steidl C, Rimsza LM, et al. HLA-DR protein expression correlates with non-neoplastic T-cell infiltration and predicts survival in patients with primary mediastinal large B-cell lymphoma (PMBCL) treated with CHOP chemotherapy. ASH Annual Meet Abstr. 2009;114(22):133.
Grant C, Dunleavy K, Eberle FC, et al. Primary mediastinal large B-cell lymphoma, classic Hodgkin lymphoma presenting in the mediastinum and mediastinal gray zone lymphoma: what is the oncologist to do? Curr Hematol Malig Rep. 2011;6(3):157–63.
FeuerhakeFKutokJLMontiSNFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypesBlood20051064139291587017710.1182/blood-2004-12-49011:CAS:528:DC%2BD2MXosVejt7c%3D
GuiterCDusanter-FourtICopie-BergmanCConstitutive STAT6 activation in primary mediastinal large B-cell lymphomaBlood2004104254391504425110.1182/blood-2003-10-35451:CAS:528:DC%2BD2cXlvFSmsrg%3D
Hamlin PA, Portlock CS, Strauss DJ, et al. Primary mediastinal large B-cell lymphoma: optimal therapy and prog
AR Filippi (219_CR53) 2013; 87
C Guiter (219_CR28) 2004; 104
219_CR61
BJ Chen (219_CR35) 2013; 19
R Cairoli (219_CR63) 2002; 29
219_CR26
219_CR27
219_CR20
R Schmitz (219_CR24) 2009; 206
219_CR65
219_CR62
219_CR8
219_CR9
C Steidl (219_CR33) 2011; 471
219_CR5
219_CR50
219_CR6
M Rieger (219_CR45) 2011; 22
219_CR7
M Pollen (219_CR51) 2011; 86
O Ritz (219_CR29) 2009; 114
C Mello De (219_CR14) 2011; 52
219_CR17
S Saarinen (219_CR4) 2013; 121
J Rodriguez (219_CR39) 1994; 5
219_CR15
219_CR59
219_CR16
219_CR19
219_CR10
219_CR54
M Gerrard (219_CR3) 2013; 121
219_CR13
219_CR57
219_CR58
219_CR11
A Rosenwald (219_CR21) 2003; 198
219_CR55
219_CR12
FS Topalian (219_CR37) 2012; 366
219_CR56
C Steidl (219_CR22) 2011; 118
F Leithauser (219_CR18) 2001; 98
219_CR48
219_CR49
219_CR42
219_CR1
219_CR43
219_CR2
219_CR40
219_CR41
219_CR46
219_CR47
PC Bishop (219_CR60) 1999; 17
219_CR44
LM Xu (219_CR64) 2013; 54
F Feuerhake (219_CR23) 2005; 106
S Joos (219_CR25) 1996; 87
219_CR38
A Dabrowska-Iwanicka (219_CR52) 2011; 22
219_CR31
219_CR32
219_CR30
219_CR36
219_CR34
References_xml – ident: 219_CR50
  doi: 10.1007/s00277-008-0625-2
– volume: 29
  start-page: 473
  issue: 6
  year: 2002
  ident: 219_CR63
  publication-title: Bone Marrow Transplant
  doi: 10.1038/sj.bmt.1703401
  contributor:
    fullname: R Cairoli
– ident: 219_CR8
  doi: 10.1111/j.1365-2141.2005.05661.x
– volume: 52
  start-page: 1495
  issue: 8
  year: 2011
  ident: 219_CR14
  publication-title: Leuk Lymphoma
  doi: 10.3109/10428194.2011.573032
  contributor:
    fullname: C Mello De
– ident: 219_CR40
  doi: 10.1200/JCO.2006.09.2403
– ident: 219_CR26
  doi: 10.1002/gcc.20420
– ident: 219_CR36
  doi: 10.1158/1078-0432.CCR-13-3007
– ident: 219_CR17
  doi: 10.1111/j.1365-2559.2009.03462.x
– ident: 219_CR56
  doi: 10.1182/blood.V116.21.420.420
– ident: 219_CR65
  doi: 10.1200/jco.2008.26.15_suppl.19506
– ident: 219_CR49
  doi: 10.1056/NEJMoa1214561
– volume: 54
  start-page: 1684
  issue: 8
  year: 2013
  ident: 219_CR64
  publication-title: Leuk Lymphoma
  doi: 10.3109/10428194.2012.746684
  contributor:
    fullname: LM Xu
– volume: 98
  start-page: 2762
  issue: 9
  year: 2001
  ident: 219_CR18
  publication-title: Blood
  doi: 10.1182/blood.V98.9.2762
  contributor:
    fullname: F Leithauser
– ident: 219_CR30
  doi: 10.1182/blood-2004-09-3701
– volume: 121
  start-page: 278
  issue: 2
  year: 2013
  ident: 219_CR3
  publication-title: Blood
  doi: 10.1182/blood-2012-04-422709
  contributor:
    fullname: M Gerrard
– volume: 87
  start-page: 1571
  issue: 4
  year: 1996
  ident: 219_CR25
  publication-title: Blood
  doi: 10.1182/blood.V87.4.1571.bloodjournal8741571
  contributor:
    fullname: S Joos
– volume: 198
  start-page: 851
  issue: 6
  year: 2003
  ident: 219_CR21
  publication-title: J Exp Med
  doi: 10.1084/jem.20031074
  contributor:
    fullname: A Rosenwald
– ident: 219_CR44
  doi: 10.1200/JCO.1993.11.12.2306
– ident: 219_CR38
  doi: 10.1007/s11899-011-0090-1
– ident: 219_CR43
  doi: 10.1080/10428190802108870
– ident: 219_CR59
  doi: 10.1182/blood.V122.21.3046.3046
– volume: 104
  start-page: 543
  issue: 2
  year: 2004
  ident: 219_CR28
  publication-title: Blood
  doi: 10.1182/blood-2003-10-3545
  contributor:
    fullname: C Guiter
– volume: 106
  start-page: 1392
  issue: 4
  year: 2005
  ident: 219_CR23
  publication-title: Blood
  doi: 10.1182/blood-2004-12-4901
  contributor:
    fullname: F Feuerhake
– ident: 219_CR48
  doi: 10.3816/CLM.2009.n.074
– ident: 219_CR54
– ident: 219_CR12
  doi: 10.1097/01.MP.0000032534.81894.B3
– volume: 22
  start-page: 195
  issue: s4
  year: 2011
  ident: 219_CR52
  publication-title: Ann Oncol
  contributor:
    fullname: A Dabrowska-Iwanicka
– ident: 219_CR6
  doi: 10.1093/annonc/mdj030
– ident: 219_CR7
  doi: 10.1182/blood.V122.21.638.638
– ident: 219_CR1
– ident: 219_CR11
  doi: 10.1182/blood.V94.10.3567.422k06_3567_3575
– ident: 219_CR57
  doi: 10.1007/s00277-014-2043-y
– ident: 219_CR46
  doi: 10.3109/10428194.2013.810738
– ident: 219_CR55
  doi: 10.1182/blood.V122.21.4302.4302
– ident: 219_CR9
  doi: 10.1038/modpathol.2012.182
– volume: 19
  start-page: 3462
  issue: 13
  year: 2013
  ident: 219_CR35
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-13-0855
  contributor:
    fullname: BJ Chen
– ident: 219_CR20
  doi: 10.1182/blood-2003-06-1841
– ident: 219_CR5
– ident: 219_CR42
  doi: 10.1038/sj.bjc.6601460
– ident: 219_CR58
  doi: 10.1182/blood.V120.21.303.303
– volume: 114
  start-page: 1236
  issue: 6
  year: 2009
  ident: 219_CR29
  publication-title: Blood
  doi: 10.1182/blood-2009-03-209759
  contributor:
    fullname: O Ritz
– ident: 219_CR47
  doi: 10.1080/10428190802203788
– ident: 219_CR15
  doi: 10.1016/j.critrevonc.2008.07.020
– ident: 219_CR16
  doi: 10.1097/00000478-200110000-00008
– ident: 219_CR61
  doi: 10.1002/hon.2012
– ident: 219_CR27
  doi: 10.1182/blood-2010-05-282780
– ident: 219_CR41
  doi: 10.1634/theoncologist.2011-0275
– volume: 17
  start-page: 2479
  issue: 8
  year: 1999
  ident: 219_CR60
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.1999.17.8.2479
  contributor:
    fullname: PC Bishop
– ident: 219_CR19
– volume: 471
  start-page: 377
  issue: 7338
  year: 2011
  ident: 219_CR33
  publication-title: Nature
  doi: 10.1038/nature09754
  contributor:
    fullname: C Steidl
– volume: 366
  start-page: 2443
  issue: 26
  year: 2012
  ident: 219_CR37
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1200690
  contributor:
    fullname: FS Topalian
– volume: 206
  start-page: 981
  issue: 5
  year: 2009
  ident: 219_CR24
  publication-title: J Exp Med
  doi: 10.1084/jem.20090528
  contributor:
    fullname: R Schmitz
– volume: 22
  start-page: 664
  issue: 3
  year: 2011
  ident: 219_CR45
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdq418
  contributor:
    fullname: M Rieger
– ident: 219_CR2
  doi: 10.1182/asheducation-2008.1.349
– ident: 219_CR10
  doi: 10.1016/S0002-9440(10)63815-1
– volume: 5
  start-page: 847
  issue: 9
  year: 1994
  ident: 219_CR39
  publication-title: Ann Oncol
  doi: 10.1093/oxfordjournals.annonc.a059016
  contributor:
    fullname: J Rodriguez
– ident: 219_CR31
  doi: 10.1038/ng.2900
– volume: 121
  start-page: 3428
  issue: 17
  year: 2013
  ident: 219_CR4
  publication-title: Blood
  doi: 10.1182/blood-2012-06-437210
  contributor:
    fullname: S Saarinen
– ident: 219_CR13
  doi: 10.1182/blood-2005-11-4742
– ident: 219_CR62
– ident: 219_CR32
  doi: 10.1182/blood.V114.22.133.133
– volume: 86
  start-page: E61
  issue: 12
  year: 2011
  ident: 219_CR51
  publication-title: Am J Hematol
  doi: 10.1002/ajh.22165
  contributor:
    fullname: M Pollen
– ident: 219_CR34
  doi: 10.1182/blood-2013-10-535443
– volume: 87
  start-page: 311
  issue: 2
  year: 2013
  ident: 219_CR53
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2013.05.053
  contributor:
    fullname: AR Filippi
– volume: 118
  start-page: 2659
  issue: 10
  year: 2011
  ident: 219_CR22
  publication-title: Blood
  doi: 10.1182/blood-2011-05-326538
  contributor:
    fullname: C Steidl
SSID ssj0044103
Score 2.169118
SecondaryResourceType review_article
Snippet Primary mediastinal B-cell lymphoma (PMBCL) is a relatively rare lymphoma subtype affecting mainly young adults. Its molecular signature and clinical features...
SourceID pubmedcentral
crossref
pubmed
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 273
SubjectTerms Antibodies, Monoclonal, Murine-Derived - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cyclophosphamide - therapeutic use
Doxorubicin - therapeutic use
Geriatrics/Gerontology
Hematology
Humans
Immunotherapy
Lymphoma, B-Cell - diagnosis
Lymphoma, B-Cell - genetics
Lymphoma, B-Cell - pathology
Lymphoma, B-Cell - therapy
Lymphomas (G Nowakowski
Lymphomas (G Nowakowski, Section Editor)
Medicine
Medicine & Public Health
Oncology
Positron-Emission Tomography
Prednisone - therapeutic use
Prognosis
Rituximab
Section Editor
Stem Cell Transplantation
Vincristine - therapeutic use
Title Primary Mediastinal Large B-cell Lymphoma
URI https://link.springer.com/article/10.1007/s11899-014-0219-0
https://www.ncbi.nlm.nih.gov/pubmed/24952250
https://pubmed.ncbi.nlm.nih.gov/PMC4180024
Volume 9
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR3LTsMwzNpDQlx4P8Zj6oELoExt0teOY9qYYCAOTBqnKklTgSY6xLoDfD1OX9MGHHZJpcaKGtu1nfgFcBFKZALh-gTFoyAo_ULC0TIgZiRDFVFuelEa5fvoDkb23dgZV4CWVxfxpFV4JFNBvch1s3ydMG_hOlQn3lSh7uiu1DWod25f7nuF_EX9nvZDRkXpEx_PN4Uv869FlrRRqYJWwyNXfKSp6ulvZ-mAs7RioY44mbTmiWjJ79_1HNfY1Q5s5Zao0clYZxcqKt6DjYfc174Pl09ZIQpDv-IoCTT0UAeOGzdE3_cbwy9khek7P4BRv_fcHZC8sQKRqN8TwhFxjJuc2goNDOF6TIqQW67JXSodwfAQhXRyQxGZ3HGY4lQy6ZthKITCwWOHUIunsToGo638sO20uZSC2lzagnsswkfEpFRoCzXgqkBw8JF9drColKw3H-DmA735wGzAUYb5ElR3xkaJgzPeEk1KAF0de3kmfntNq2TblraF7QZcF5gP8t9z9v8XnKwFfQqbNCWdpuAZ1JLPuTpHGyURzZwpm1Dtul0cR7TzA0MO32E
link.rule.ids 230,315,786,790,891,27957,27958,41116,41155,41558,42185,42224,42627,51611,52146,52269
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV07T8MwED5BkYAF8aY8M7AAspTYeXUsiKpAWjG0UjfLr6gMpIiWgX_P2UlatYKBJZHik2V9Pt-dcy-Aa62QCWScEhSPkqD000SgZUD8XGmTU-EnuYvy7cfdYfg8ikZVHve0jnavXZJOUi-S3YLUZswHOBG1mTfrsGHLqdsb15C2a_GL6t21Q0Y9mZIUrze1K_O3KZaU0VwDrUZHrrhInebp7MJOZTJ67XKP92DNFPuw2auc4gdw81pWjPDsJ4FH1lJnNsLbuyf2x7yXfeOeTd7FIQw7j4OHLqk6IBCFinhGBCpXJnxBQ4OWgIwTpqQWQeyLmKpIMrztIKCxlrkvoogZQRVTqa-1lAYfCTuCRjEpzAl4LZPqVtQSSkkaChVKkbAcXzlTyqDR0oTbGgr-US6bL0oaW9w44sYtbtxvwnGJ0ZzUtrBG0YAjyRJ6cwJbxnp5pHgbu3LWYWCN1rAJdzXOvDpH079XcPov6ivY6g56Gc-e-i9nsE0dB1hGOIfG7PPLXKBhMZOXjpF-AKM1xKs
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LT8JAEJ4oJsSL8S0-e_CiZkO72xdHfBBUJBwk4dbsq9GDhQge_PfO9AGB6MFLm3Qnm823szOznRfApdHIBCqMGYpHxVD6GSbRMmBuqo1NuXSjNI_y7Yfdof80CkZln9NpFe1euSSLnAaq0pTNmhOTNheJb15M2fMeTsopC2cdNkgzUkzXkLcrUYyqPm-NTCMsxqtO5db8bYolxTTXRquRkivu0lwLdbZhqzQfnXax3zuwZrNdqL-UDvI9uBoU1SMc-iTx-BJ1j6K9nVtGP-md3jfu3_hD7sOw8_B612VlNwSmUSnPmERFK6QruW_RKlBhJLQy0gtdGXIdKIE3HwQ3NCp1ZRAIK7kWOnaNUcriIxIHUMvGmT0Cp2Vj0wpaUmvFfal9JSOR4isVWls0YBpwXUGRTIplJ4vyxoRbgrglhFviNuCwwGhOSu2sUUzgSLSE3pyASlovj2Tvb3lpa98jA9ZvwE2Fc1KeqenfKzj-F_UF1Af3naT32H8-gU2eMwDxwSnUZp9f9gxtjJk6z_noB0xeyPA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Primary+Mediastinal+Large+B-cell+Lymphoma&rft.jtitle=Current+hematologic+malignancy+reports&rft.au=Dabrowska-Iwanicka%2C+Anna&rft.au=Walewski%2C+Jan+A.&rft.date=2014-09-01&rft.pub=Springer+US&rft.issn=1558-8211&rft.eissn=1558-822X&rft.volume=9&rft.issue=3&rft.spage=273&rft.epage=283&rft_id=info:doi/10.1007%2Fs11899-014-0219-0&rft_id=info%3Apmid%2F24952250&rft.externalDBID=PMC4180024
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1558-8211&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1558-8211&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1558-8211&client=summon